UBS initiated coverage on Certara with a new price target
$CERT
Computer Software: Prepackaged Software
Technology
UBS initiated coverage of Certara with a rating of Neutral and set a new price target of $17.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/21/2025 | $10.00 | Buy | Rothschild & Co Redburn |
| 11/13/2025 | $9.00 | Market Perform | BMO Capital Markets |
| 9/29/2025 | $16.00 | Buy | Craig Hallum |
| 7/3/2025 | $16.00 | Equal-Weight | Morgan Stanley |
| 5/8/2025 | $14.00 | Equal Weight → Overweight | Barclays |
| 2/27/2025 | $16.00 | Buy | TD Cowen |
| 9/27/2024 | $16.00 | Neutral → Buy | UBS |
| 4/10/2024 | $23.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
Issued on behalf of Aleen Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies are cutting drug discovery timelines by 30% or more through AI models that predict molecular behavior before researchers invest months in testing, marking a fundamental shift from traditional trial-and-error approaches to computational creation of biological solutions[1]. The generative AI healthcare market is projected to surge from $2.64B in 2025 to $39.70B by 2034, reflecting the technology's expansion from simple data analysis to active creation and interpretation of therapeutic compounds[2]. This Platform-First revolution is extending rapidly into c
VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Healthcare organizations are setting the pace for enterprise AI adoption as operational automation moves from experimentation to production scale across hospital systems[1]. The shift reflects a fundamental change in how healthcare leaders view AI technology, with deployment projected to expand the global healthcare AI market from $17.2 billion in 2025 to $77.2 billion by 2035[2]. Five publicly traded companies are positioned at the intersection of this operational transformation, delivering infrastructure that turns AI capabilities into measurable workflow improvements and financial returns
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief Executive Officer and member of Certara's Board of Directors, effective January 1, 2026, succeeding William F. Feehery, who will at that point serve as an external advisor during a transition period. Resnick brings over 20 years of experience with IQVIA, a g
Rothschild & Co Redburn initiated coverage of Certara with a rating of Buy and set a new price target of $10.00
BMO Capital Markets initiated coverage of Certara with a rating of Market Perform and set a new price target of $9.00
Craig Hallum initiated coverage of Certara with a rating of Buy and set a new price target of $16.00
8-K - Certara, Inc. (0001827090) (Filer)
SCHEDULE 13G/A - Certara, Inc. (0001827090) (Subject)
SCHEDULE 13G - Certara, Inc. (0001827090) (Subject)
4 - Certara, Inc. (0001827090) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief Executive Officer and member of Certara's Board of Directors, effective January 1, 2026, succeeding William F. Feehery, who will at that point serve as an external advisor during a transition period. Resnick brings over 20 years of experience with IQVIA, a g
RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology. Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t
RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%.Services revenue was $60.8 million, compared to $58.9 million in the third quarter of 2024, representing growth of 3%. Net income was $1.5 million, compared to a net loss of $1.4 million in the third quarter of 2024, representing
RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close on Thursday, November 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using biosimulation softw
RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 million, compared to $93.3 million in the second quarter of 2024, representing growth of 12%. Software revenue was $46.7 million, compared to $38.2 million in the second quarter of 2024, representing growth of 22%.Service revenue was $57.9 million, compared to $55.1 million in the second quarter of 2024, representing growth of 5%. Net loss was $2.0 million, compared to a net loss of $12.6 million in the second quarter of 2024, repr
SC 13G - Certara, Inc. (0001827090) (Subject)
SC 13G/A - Certara, Inc. (0001827090) (Subject)
SC 13G/A - Certara, Inc. (0001827090) (Subject)